Clinical trials: ST-Segment Elevation Myocardial Infarction
Survival Myocardial Area After Acute Myocardial Death, Left Ventricular Ejection Fraction
Clinical Study of Cardiomyopeptidin on Postoperative Ischemia-reperfusion Injury in Patients With Primary PCI
In this study, advanced techniques of myocardial nuclear magnetic perfusion scanning were used to quantitatively assess infarct size after acute myocardial infarction, saved viable myocardium, and microcirculatory obstruction…
- Trial name
- NCT03958422
- Testing
- cardiomyopeptidin
- Volunteers
- 160 people
- Sponsor
- Dalian Zhen-Ao Bio-Tech Co., Ltd.
Myocardial Infarction, Coronary Arteriosclerosis
Randomized Clinical Trial of Adipose-Derived Stem Cells in the Treatment of Pts With ST-elevation Myocardial Infarction
The purpose of this study is to establish safety and feasibility of utilizing Adipose-Derived Stem and Regenerative Cells (ADRC's) in patients who have suffered a ST-elevation acute myocardial infarction.
- Conditions
- Myocardial Infarction, Coronary Arteriosclerosis, Cardiovascular Disease, Coronary Disease
- Trial name
- NCT00442806
- Testing
- Injection of ADRC's
- Where
- 2 sites in Netherlands, Spain
- Volunteers
- 14 people
- Sponsor
- Cytori Therapeutics
STEMI - ST Elevation Myocardial Infarction, AMI
SuperSaturated Oxygen Comprehensive Observational Registry
The SuperSaturated Oxygen Comprehensive Observational Registry (SSCORE) registry, a prospectively designed observational study, aims to evaluate the clinical utility, infarct size reduction, and cost-effectiveness of SSO2 Therapy…
- Trial name
- SSCORE (NCT06438315)
- Testing
- KCCQ, Eq5D, cMRI (Subset of patients)
- Where
- 25 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- TherOx
STEMI
The Coronary Sinus Balloon Pump in STEMI
This study is a prospective, multicenter, randomized controlled clinical trial designed to evaluate the safety and efficacy of the coronary sinus balloon pump (manufactured by Shanghai MicroPort Rotapace Medical Technology Co.…
- Trial name
- REVIVE-RCT (NCT07354035)
- Testing
- The coronary sinus balloon pump, Percutaneous Coronary Intervention (PCI)
- Volunteers
- 177 people
- Sponsor
- Shanghai MicroPort Rhythm MedTech Co., Ltd.
ST-elevation Myocardial Infarction (STEMI)
A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI
This is a Phase 3 prospective, blinded, randomized, placebo controlled, international multicenter study. Subjects with STEMI will be enrolled in the ambulance if they meet all eligibility criteria.
- Trial name
- CELEBRATE (NCT04825743)
- Testing
- zalunfiban
- Where
- 45 sites in United States, Canada and 6 more
- Volunteers
- 2,463 people
- Sponsor
- CeleCor Therapeutics
Acute Myocardial Infarction (AMI)
Artificial Intelligence Scalable Solution for ST Myocardial Infarction
The ASSIST clinical study is an observational, multicenter study to assess the performance of a cloud-based and AI-powered electrocardiogram (ECG) analysis platform, named Willem™, developed to detect Acute Myocardial Infarction…
- Trial name
- ASSIST (NCT06939738)
- Where
- 5 sites in Portugal, Spain
- Volunteers
- 489 people
- Sponsor
- Idoven 1903 S.L.
Acute Myocardial Infarction
Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI
The purpose of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily.
- Trial name
- PARADISE-MI (NCT02924727)
- Testing
- LCZ696 (sacubitril/valsartan), Ramipril, Valsartan
- Where
- 486 sites in United States, Argentina and 39 more
- Volunteers
- 5,669 people
- Sponsor
- Novartis Pharmaceuticals
Myocardial Infarction (MI), Acute Coronary Syndromes (ACS)
A Clinical Trial to Demonstrate the Efficacy of Cangrelor
The primary objective of this study is to demonstrate that the efficacy of cangrelor is superior, or at least non-inferior, to that of clopidogrel in subjects requiring PCI.
- Trial name
- PCI (NCT00305162)
- Testing
- Cangrelor (P2Y12 inhibitor), clopidogrel (oral P2Y12 inhibitor)
- Where
- United States
- Volunteers
- 8,882 people
- Sponsor
- The Medicines Company
Myocardial Infarction, Segment Elevation Myocardial Infarction (STEMI)
A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)
The aim of this study is to determine whether initiation of ticagrelor as early as in the ambulance setting leads to a rapid reperfusion of the infarct-related artery therefore facilitating the Percutaneous Coronary Intervention…
- Trial name
- ATLANTIC (NCT01347580)
- Testing
- Ticagrelor
- Where
- 96 sites in Algeria, Australia and 11 more
- Volunteers
- 1,875 people
- Sponsor
- AstraZeneca
Acute Myocardial Infarction
Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction
This was a double-blind, randomized, placebo-controlled study that was designed to enroll a total of 225 participants with de novo anterior wall acute ST-segment elevation myocardial infarction (STEMI) due to a lesion of the left…
- Trial name
- AMICI (NCT01781390)
- Testing
- Mesenchymal Precursor Cells (MPC) 12.5 M, Mesenchymal Precursor Cells (MPC) 25 M
- Volunteers
- 106 people
- Sponsor
- Mesoblast, Inc.
Myocardial Infarction
A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention
This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of RO4905417 in patients with non ST-elevation myocardial infarction (Non-STEMI) undergoing percutaneous coronary intervention (PCI).
- Trial name
- NCT01327183
- Testing
- Percutaneous Coronary Intervention (PCI), RO4905417
- Where
- 66 sites in United States, Canada and 2 more
- Volunteers
- 532 people
- Sponsor
- Hoffmann-La Roche
Acute Myocardial Infarction, Non-ST Elevation Myocardial Infarction
Impact of Cardiac Rehabilitation Programs on Left Ventricular Remodeling After Acute Myocardial Infarction - the REHAB Trial
The aim of REHAB trial is to investigate the impact of early mobilization after AMI in reducing left ventricular remodeling, as assessed by cardiac magnetic resonance imaging.
- Conditions
- Acute Myocardial Infarction, Non-ST Elevation Myocardial Infarction, Systemic Inflammation, Ventricular Remodeling
- Trial name
- NCT04161378
- Testing
- Cardiac imaging, Laboratory analysis
- Where
- Romania
- Volunteers
- 100 people
- Sponsor
- Cardio Med Medical Center
STEMI, Dyslipidemias
The Safety and Long-Term Clinical Benefit of PCSK9i in STEMI Patients
Patients with acute coronary syndromes (ACS) have an increased risk of recurrent ischemic events, particularly during the first year following the index event, which is mainly due to unattended risk factors and/ or poor…
- Trial name
- NCT05579418
- Testing
- Evolocumab
- Volunteers
- 350 people
- Sponsor
- Hamad Medical Corporation
Focus of Study is STEMI
Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction
This study explores the potential cardioprotective properties of danegaptide when administered to patients with ST-Segment elevation myocardial infarction.
- Trial name
- NCT01977755
- Testing
- danegaptide
- Where
- Denmark
- Volunteers
- 591 people
- Sponsor
- Zealand Pharma
Acute Myocardial Infarction, STEMI
Evaluation in STEMI Patients Using FDY-5301
To assess the effect of FDY-5301 on cardiovascular mortality and acute heart failure events in subjects with an anterior STEMI undergoing pPCI.
- Conditions
- Acute Myocardial Infarction, STEMI, Percutaneous Coronary Revascularization
- Trial name
- IOCYTE AMI-3 (NCT04837001)
- Testing
- FDY-5301
- Where
- 52 sites in United States, Canada and 4 more
- Volunteers
- 2,351 people
- Sponsor
- Faraday Pharmaceuticals, Inc.
Acute Anterior Myocardial Infarction
The INFUSE - Anterior Myocardial Infarction (AMI) Study
This is a multicenter, open-label, controlled, single-blind, randomized study with up to 452 subjects enrolled in up to 50 US and European sites.
- Trial name
- NCT00976521
- Testing
- Abciximab local infusion, No local infusion, Thrombus aspiration
- Where
- 38 sites in United States, Austria and 4 more
- Volunteers
- 452 people
- Sponsor
- Atrium Medical Corporation
Non ST Segment Elevation Myocardial Infarction, Unstable Angina
Patients With High-risk Acute Coronary Syndrome Without ST-segment Elevation
This non-inferiority study aims at comparing Versa® to the reference enoxaparin (Clexane®, Sanofi-Aventis) in patients with high-risk unstable angina and NSTEMI.
- Trial name
- VECOR (NCT01356992)
- Testing
- Enoxaparin
- Where
- 5 sites in Brazil
- Volunteers
- 62 people
- Sponsor
- Eurofarma Laboratorios S.A.
Coronary Artery Disease
BIOFLOW III Satellite-ELADIS Orsiro Stent System
This registry is a clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES).
- Trial name
- NCT02029092
- Where
- 14 sites in Spain
- Volunteers
- 404 people
- Sponsor
- C.E.M. Biotronik, S.A.
Coronary Artery Disease, Stable Angina
BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM
Prospective, multi-center, registry designed to enrol up to 2,000 patients in up to 35 International centers. All patients will receive a BioMatrix AlphaTM stent as per clinical practice and will be followed for 2 years for data…
- Conditions
- Coronary Artery Disease, Stable Angina, Ischemia, Acute Coronary Syndrome
- Trial name
- NCT02871622
- Testing
- BioMatrix AlphaTM
- Where
- United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Biosensors Europe SA
Acute Coronary Syndrome
Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)
The purpose of this study is to compare the safety of two different dose regimens of unfractionated heparin (UFH) during a percutaneous coronary intervention (PCI) procedure in patients with UA (unstable angina)/NSTEMI (non ST…
- Trial name
- FUTURA/OASIS 8 (NCT00790907)
- Testing
- fondaparinux background and standard dose UFH, Fondaparinux background and low dose heparin, Open label fondaparinux
- Where
- 203 sites in United States, Argentina and 16 more
- Volunteers
- 3,235 people
- Sponsor
- GlaxoSmithKline